TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target
TD Cowen analyst Ryan Langston reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $19 price target.
Stocks · News reference
Surgery Partners Affirms FY2026 Sales Guidance of $3.350B-$3.450B vs $3.408B Est
Surgery Partners (NASDAQ:SGRY) affirms FY2026 sales outlook from $3.350 billion-$3.450 billion to $3.350 billion-$3.450 billion vs $3.408 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Surgery Partners Updates FY2026 Revenue Guidance To $3.08B-$3.18B, Adjusted EBITDA To At Least $489M Following Idaho Falls Sale
8-K filing — Surgery Partners, Inc. (SGRY)
Filed: 2026-09-17 AccNo: 0001638833-26-000085 Size: 769 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits
Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised price targets for Meta, IREN, Coinbase, Roblox and others; IREN and Coinbase were upgraded, while other ratings held steady.